	US 12,186,282 B2
	Treatment of 22Q11.2 deletion syndrome with cannabidiol
Terri Sebree, Gladwyne, PA (US); and Donna Gutterman, Raleigh, NC (US)
Assigned to HARMONY BIOSCIENCES MANAGEMENT, INC., Plymouth Meeting, PA (US)
Filed by Harmony Biosciences Management, Inc., Plymouth Meeting, PA (US)
Filed on Sep. 30, 2022, as Appl. No. 17/957,932.
Application 17/957,932 is a continuation of application No. 16/712,066, filed on Dec. 12, 2019, granted, now 11,458,109, issued on Oct. 4, 2022.
Claims priority of provisional application 62/895,279, filed on Sep. 3, 2019.
Claims priority of provisional application 62/779,591, filed on Dec. 14, 2018.
Prior Publication US 2023/0024756 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61P 25/22 (2006.01)

CPC A61K 31/05 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61P 25/22 (2018.01)]

20 Claims

1. A method of treating one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome in a subject, the method comprising:

administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject.